The combined technique offers a promising way to increase the effectiveness of anti-CTLA4 immunotherapy in HNSCC by reducing myeloid-derived suppressor cells and Tregs while increasing the ratio of CD8+ T cells to Tregs [30,31,32,33,34,35]. This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.